PharmAust has kicked-off its much-anticipated Phase II clinical trials that will study the effectiveness of the new palatable and high dose tablet formulation of its Monepantel anti-cancer drug in dogs. The trial will determine the efficacy of the drug over a prolonged period of time in dogs with B cell lymphoma before testing progresses to low dose maintenance of progression free survival and efficacy in other cancers.
Related Data & Insights
-
-
Rank Company Revenue 128th PharmAust $3.8m 129th ResApp Health $3.8m 130th Emyria $3.8m 132nd Botanix Pharmaceuticals $3.8m 133rd Volt Power Group $3.6m 200 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Related Articles
05 Feb 2024
Board Moves February 5, 2024
28 Aug 2023
Board Moves August 28, 2023
23 Jul 2021
PharmAust looks to patent anti-cancer drug
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX